AMBU-B

Ambu is a medical device company that delivers solutions in endoscopy, anesthesia, and patient monitoring. Its business segments include Endoscopy Solutions and Anesthesia & Patient Monitoring. The company provides single-use endoscopes for pulmonology, urology, ear-nose-throat (ENT), and gastroenterology, operating on the aScope platform. Its anesthesia and monitoring portfolio includes the Ambu bag, SureSight video laryngoscope, and ECG electrodes. Ambu acquired TIMS Medical to advance its EndoIntelligence capabilities. The company serves healthcare professionals, hospitals, and health systems globally, with North America as its largest market. It was founded in 1937.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Medical Devices Homepage ambu.com
Sector Healthcare IR page ambu.com/corporate-info/investors
Tags
single-use endoscopy, anesthesia equipment, patient monitoring, video laryngoscope, resuscitators, ecg electrodes, medical consumables, critical care diagnostics, aScope, Ambu bag, SureSight, Neuroline, aScope 5 Broncho, aScope Gastro Large, aScope 5 Cysto HD, TIMS Medical, EndoIntelligence
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E 38.95
PEG 0.45
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE 10.5%
ROI 10.1%
ROIC 13.0%
Profit margin 10.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 87.1%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock —
Diluting (TTM) —
Debt/Equity 0.08%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 35
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 6.037B 5.391B 4.775B 4.444B 4.013B
Net profit 609M 235M 168M 93M 247M

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

FINANCIAL CALENDAR 2026/27 30.9.2026 12:57:22 CEST | Ambu A/S | Financial Calendar

This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2026/27, as well as the date of Ambu’s annual general meeting.

2026 5 November 2026

Annual Report 2025/26

2 December 2026

Annual general meeting

2027 28 January 2027

Earnings Release Q1 2026/27

5 May 2027

Earnings Release Q2 2026/27

25 August 2027

Earnings Release Q3 2026/27

30 September 2027

End of fiscal year 2026/27

10 November 2027

Annual Report 2026/27

8 December 2027

Annual general meeting

Deadline for the inclusion of specific items on the agenda for the annual general meeting 2026 is 20 October 2026.

Company announcement no. 19 2025/26.

PRESS RELEASE 28 September 2026

AMBU APPOINTS BOARD OBSERVER, PLANS BOARD MEMBER NOMINATION Current Grifols CEO and former Olympus executive, Nacho Abia, brings more than 20 years of leadership experience across global healthcare and endoscopy.

Copenhagen, Denmark, 28 September 2026 – Ambu, the global market leader in single-use endoscopy, today announces that Jose Ignacio (Nacho) Abia Buenache has been appointed as an observer to Ambu’s Board of Directors and will be proposed for election as a member of the Board at the Company’s upcoming annual general meeting on 2 December 2026. Nacho Abia currently serves as Chief Executive Officer and member of the Board of Directors of Grifols, a global pharmaceutical company with annual revenue exceeding EUR 7 billion. Prior to joining Grifols in 2024, Abia spent more than two decades at Olympus Corporation, where he held several senior executive positions, including Global Chief Operating Officer, Chief Executive Officer of Olympus Americas, and Global Chief Strategy Officer. “I am excited to welcome Nacho Abia as a board observer to Ambu’s Board of Directors,” says Jørgen Jensen, Chair of Ambu’s Board of Directors. “Nacho brings a strong combination of global healthcare leadership, endoscopy knowledge, and a proven track record of driving innovation, execution, and growth. His experience will be a significant asset to the Board as we continue to realize Ambu’s substantial long-term potential.” “Ambu is a pioneer in single-use endoscopy and has demonstrated how innovation, a strong culture, and close collaboration with clinicians can challenge established practices and create meaningful value for healthcare professionals and patients,” says Nacho Abia. “I believe Ambu is uniquely positioned to continue advancing endoscopy and expand the impact of single-use solutions globally. The company has a strong foundation, a clear strategic direction, and significant opportunities ahead. I look forward to working closely with the Board and Executive Management to support Ambu’s continued growth and help shape the evolution of endoscopy.”

Ambu A/S Baltorpbakken 13 2750 Ballerup Denmark Tel. +45 7225 2000 CVR no.: 63 64 49 19 www.Ambu.com

Download the company announcement here Bull 1 Bear 0 Routine

AMBU'S SHARE BUYBACK PROGRAM HAS BEEN FINALIZED 21.9.2026 09:33:31 CEST | Ambu A/S | Changes in company's own shares

On 6 May 2026, Ambu announced a share buyback program (company announcement no. 12 2025/26). The share buyback program was carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations. During the program, Ambu has repurchased shares for a total amount of DKK 300m since 6 May 2026. The program had to be completed no later than 30 September 2026. The repurchased shares are bought with the aim of completing a share capital decrease as set out in Article 5(2)(a) in MAR. The following transactions have been made under the program from 14 September 2026 to 18 September 2026: Number of shares

Average purchase price, DKK

Transaction value, DKK

Accumulated under the program after last announcement

4,285,739

66.8453

286,481,417

2026.09.14

8,893

65.9167

586,198

2026.09.15

76,529

65.3917

5,004,360

2026.09.16

110,000

65.5437

7,209,807

2026.09.17

5,000

66.0307

330,154

2026.09.18

5,915

65.5965

388,003

Accumulated under the program

4,492,076

66.7843

299,999,938

After the above mentioned transactions, the share buyback program has now been concluded. Ambu now owns 8,641,687 treasury shares, corresponding to 3.2% of the share capital.

Prompts

Ambu (ticker AMBU-B), listed in Denmark.

ETFs Holding Ambu

ETF Weight in ETF Shares Market value As of
IGGY 1.81% 7,316 $ 80.887K Aug 31, 2026
DFIS 0.06% 279,808 $ 3.614M Nov 12, 2026
DFAX 0.02% 145,539 $ 1.88M Nov 12, 2026
DFIC 0.01% 131,547 $ 1.699M Nov 12, 2026
AVDS 0.01% 3,028 $ 40.418K Nov 16, 2026
DFAI 0.01% 122,454 $ 1.582M Nov 12, 2026
DFSI 0.01% 6,023 $ 77.794K Nov 12, 2026
NTSI 0.01% 3,137 $ 29.268K Jun 30, 2026